Mindestbestellung 120 EUR Kostenlose Lieferung ab 250 EUR Bereit zur Abholung dead drop: in 5 Min. abholen Kostenloser Versand ab 250 EUR Aktionen

Substanzen · Benzodiazepine und Thienodiazepine

Pyrazolam

C16H12BrN5 CAS 39243-02-2 Nur für analytische Forschungszwecke — nicht für den menschlichen Verzehr
Bevorzugter Name
Pyrazolam
IUPAC-Name
8-bromo-1-methyl-6-pyridin-2-yl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
CAS-Nummer der Stammverbindung (Referenz)
39243-02-2
Summenformel
C16H12BrN5
Molekulargewicht
354.2 g/mol
InChIKey
BGRWSFIQQPVEML-UHFFFAOYSA-N
PubChem
CID 12562545
Quelle
PubChem
Geprüfte Synonyme und Katalogkürzel
SH-I-04 Pyridinyl-bromazolam

Passende Artikel im aktuellen Shop-Katalog

Geprüftes Pharmakologie- & Toxikologie-Dossier

Pyrazolam

Alpha2/Alpha3-Leaning Anxiolytic GABA-A PAM Triazolobenzodiazepine
Geprüfte PubChem- & CAS-Identität C16H12BrN5 · CAS 39243-02-2 · CID 12562545
Kalibrierte Lieferform Präzisionstabletten · 1 Tablette = 1 mg
≥98 % analytische Reinheit geprüft 354.2 g/mol
WHO-, PubMed- & PubChem-Quellen 2 cited records

Rezeptor-Telemetrie & Wirkmechanismus

GABAₐ α₂/α₃ Anxiolysis & Myorelaxation High PAM
GABAₐ α₁ Hypnotic / Sedative Drive Selective
GABAₐ α₅ Amnestic / Cognitive Modulation Moderate

Pyridinyl-bromotriazolobenzodiazepine exhibiting preferential functional selectivity toward alpha2 and alpha3 GABA-A subunits over hypnotic alpha1 subunits.

Biotransformation & Active Metabolites

Excreted largely unchanged renally with minimal hepatic Phase I active metabolites.

Zeitliche Pharmakokinetik

Alpha2/Alpha3-Leaning Anxiolytic GABA-A PAM — 1 tablet = 1 mg lies cleanly in the functional anxiolytic range; distinguished from Bromazolam and Flualprazolam by minimal hepatic metabolism and noticeably lower alpha1 drowsiness at equivalent anxiolytic levels.

  1. Onset 15–35 min
  2. Peak Window 1–2.5 h
  3. Total Window 5–8 h
  4. Residual / Half-Life 4–10 h minimal metabolite tail

1 tablet = 1 mg lies cleanly in the functional anxiolytic range; distinguished from Bromazolam and Flualprazolam by minimal hepatic metabolism and noticeably lower alpha1 drowsiness at equivalent anxiolytic levels.

Quantitatives Wirkungsspektrum (Literaturdaten)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
0.5 mg
Cognitive & Sensory

Subtle threshold receptor activity (Alpha2/Alpha3-Leaning Anxiolytic GABA-A PAM).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
0.5–1 mg
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
1–2 mg
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
2–3 mg
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
4+ mg
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Wechselwirkungsmatrix — Niemals kombinieren

Lebensgefahr — Niemals kombinieren

Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl)

Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.

Alcohol, GHB/GBL, and Barbiturates

Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.

Hohes Risiko — Vermeiden

Dissociatives (Ketamine, 2-FDCK, DCK, O-PCE, MXE)

Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.

Vorsicht / Abschwächung

CYP3A4 inhibitors (grapefruit juice, ketoconazole) & Stimulants

CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.

Isomeren- & Strukturvergleich

1 tablet = 1 mg lies cleanly in the functional anxiolytic range; distinguished from Bromazolam and Flualprazolam by minimal hepatic metabolism and noticeably lower alpha1 drowsiness at equivalent anxiolytic levels.

Stabilität & Lagerung

Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.

Store sealed in a cool, dry, light-protected container away from humidity.

Cross-Tolerance & Dependence Profile

Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.

Analytische & toxikologische Monographie

Pyrazolam (8-bromo-1-methyl-6-pyridin-2-yl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; CAS 39243-02-2, PubChem CID 12562545) is a triazolobenzodiazepine reference compound (C16H12BrN5, 354.2 g/mol) classified pharmacologically as a Alpha2/Alpha3-Leaning Anxiolytic GABA-A PAM. Pyridinyl-bromotriazolobenzodiazepine exhibiting preferential functional selectivity toward alpha2 and alpha3 GABA-A subunits over hypnotic alpha1 subunits. Excreted largely unchanged renally with minimal hepatic Phase I active metabolites. In published observational and toxicological literature, threshold response is noted at 0.5 mg, light range at 0.5–1 mg, common reference range at 1–2 mg, strong intensity at 2–3 mg, and heavy/adverse territory at 4+ mg, with an onset of 15–35 min, peak window of 1–2.5 h, and total duration of 5–8 h (4–10 h minimal metabolite tail). 1 tablet = 1 mg lies cleanly in the functional anxiolytic range; distinguished from Bromazolam and Flualprazolam by minimal hepatic metabolism and noticeably lower alpha1 drowsiness at equivalent anxiolytic levels. Critical contraindications include Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl), Alcohol, GHB/GBL, and Barbiturates.

Chemische Struktur und Molekülprofil

Pyrazolam (8-bromo-1-methyl-6-pyridin-2-yl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) ist eine Referenzverbindung aus der Stoffklasse Benzodiazepine und Thienodiazepine mit der Summenformel C16H12BrN5 und einer molaren Masse von 354.2 g/mol. Die Stammverbindung wird unter der CAS-Nummer 39243-02-2 sowie in der NCBI-PubChem-Datenbank unter CID 12562545 geführt (Standard-InChIKey: BGRWSFIQQPVEML-UHFFFAOYSA-N).

Quellen

Referenztoxikologie und Sicherheitsprofil

Laut dokumentierten Referenzdaten (PubChem / PsychonautWiki, CC BY 4.0) gehört Pyrazolam zur chemischen Klasse Benzodiazepines. Toxikologische Hinweise (PsychonautWiki): geringe Eigen-Toxizität; Kombinationen mit Depressiva (Alkohol, Opioide) sind lebensgefährlich. Abhängigkeitspotenzial (PsychonautWiki): sehr hohes physisches und psychisches Abhängigkeitspotenzial. Dokumentierte Kreuztoleranz: benzodiazepines. Beim Umgang im Labor sind geeignete persönliche Schutzausrüstung und das Sicherheitsdatenblatt (SDB) zu beachten.

Quellen

Analytischer Verwendungszweck und Laborhinweis

Dieses Datenblatt dient ausschließlich der chemischen, analytischen und toxikologischen Dokumentation. Das Material ist nicht für den menschlichen Verzehr bestimmt. Ein Forschungshinweis begründet keinen Rechtsstatus.

Quellen